English to Russian Medical Medical: Pharmaceuticals

Follow-up: range 6 to 36 months
Moderated
FEV1 (L)
Follow-up:
12 months
Mean lung function:
We are moderately confident in the effect estimate:
Figure 1.
Primary outcomes
Pneumonia
Secondary outcomes
Lung function
2016 = 15
Comparison 2:
Sensitivity analysis
Comparison
Alfageme 2006
Davis 1987
Dransfield 2009
Furumoto 2008
Kostinov 2014
Leech 1987
Lin 2013
Steentoft 2006
Teramoto 2007
Trofimov 2010
Ya Tseimakh 2006
Yilmaz 2013
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding (performance bias and detection bias)
Blinding of participants and personnel (performance bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Pneumococcal Vaccine
Control
Odds Ratio
Risk of Bias
Study or Subgroup
Events
Total
Weight
M-H, Fixed, 95% CI
A B C D E F G
1.1.1 PPV-23 serotypes
Alfageme 2006 (1)252983329841.4%0.74 [0.43, 1.27]
Furumoto 2008 (2)6245314.5%1.73 [0.46, 6.56]
Steentoft 2006 (3)11375127.3%0.59 [0.15, 2.28]
Subtotal (95% CI)75651395.0%0.61 [0.42, 0.89]
Total events6077
Heterogeneity:
Chi2 = 5.42, df = 4 (P = 0.25); I2 = 26%
Test for overall effect:
Z = 2.57 (P = 0.01)
Davis 1987 (6)3504535.0%0.78 [0.17, 3.68]
Not applicable
Total (95% CI)806566100.0%0.62 [0.43, 0.89]
Test for subgroup differences:
Footnotes
(1) 32 months median
(2) 24 months
**Risks of bias legend**
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)
(C) Blinding (performance and detection bias)